TRexBio
PVT · PVT·South San Francisco, CA·Private·Phase 1
Clinical-stage immunology company discovering medicines based on tissue-resident regulatory T cell biology. Deep Biology Platform maps human tissue Treg behavior to identify novel targets for autoimmune and inflammatory diseases. Partnerships with Eli Lilly and Johnson & Johnson; raised $134M+ including a $50M financing in January 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| TRexBio website | Website | May 5, 2026 | 3 |